Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.47 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.47 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467135 | 1.00 | KCNQ3 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL27503767 | 0.86 | KCNQ3 (0.44) | KCNQ3KCNQ2KCNE1KCNQ1KMO | |
| SCHEMBL30025571 | 0.86 | GSK3B (0.53) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL3502522 | 0.86 | KCNQ3 (0.46) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL2630705 | 0.86 | GSK3B (0.53) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL29499477 | 0.85 | GSK3B (0.55) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL13116542 | 0.85 | KCNQ3 (0.45) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL3973133 | 0.85 | GSK3B (0.55) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL18538090 | 0.85 | MAPT (0.54) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL2273688 | 0.83 | CES2 (0.61) | KCNQ3KCNQ2KCNQ5CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0188194-B1 | AMINOACRYLIC ACID DERIVATIVES | BAYER AG (DE) | 1990-07-04 | — | — | EP | claimed |
| EP-0188194-A2 | Aminoacrylic acid derivatives | BAYER AG (DE) | 1986-07-23 | — | — | EP | claimed |
| CN-86100221-A | AMINOACRYLIC ACID DERIVATIVES | — | 1986-07-16 | — | — | CN | claimed |
| EP-3494971-B1 | SALTS OF ERK INHIBITORS | GENENTECH INC (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-111777594-B | Method for preparing a medicament | 基因泰克公司 | 2023-06-27 | — | — | CN | disclosed |
| US-11066389-B2 | Process for the manufacturing of medicaments | GENENTECH, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066389-B2 | Process for the manufacturing of medicaments | GENENTECH, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200190061-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200190061-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-10611753-B2 | Process for the manufacturing of medicaments | GENENTECH, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-10611753-B2 | Process for the manufacturing of medicaments | GENENTECH, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| EP-0807629-B1 | Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them | AVENTIS PHARMA GMBH (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-6191164-B1 | POTASSIUM CHANNEL MODULATORS; ANTIULCER AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-02-20 | — | — | US | disclosed |
| US-6071953-A | Sulfonamide-substituted chromans, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-06-06 | — | — | US | disclosed |
| EP-0860440-A1 | Sulfonamido substituted chromane derivatives with potassium channel blocking activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-08-26 | — | — | EP | disclosed |
| EP-0807629-A1 | Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-19 | — | — | EP | disclosed |
| EP-0188194-B1 | AMINOACRYLIC ACID DERIVATIVES | BAYER AG (DE) | 1990-07-04 | — | — | EP | disclosed |
| US-4695646-A | OXYQUINOLINECARBOXYLIC ACID INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 1987-09-22 | — | — | US | disclosed |
| EP-0188194-A2 | Aminoacrylic acid derivatives | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| CN-86100221-A | AMINOACRYLIC ACID DERIVATIVES | — | 1986-07-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611753-B2 | Process for the manufacturing of medicaments | ARSA, F8, CYP4A11 | KCNQ3 1109/4885KCNQ2 1053/4885KCNE1 1776/4885 |
| US-11066389-B2 | Process for the manufacturing of medicaments | ARSA, F8, CYP4A11 | KCNQ3 1109/4885KCNQ2 1053/4885KCNE1 1776/4885 |
| US-20200190061-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | ARSA, F8, CYP4A11 | KCNQ3 1109/4885KCNQ2 1053/4885KCNE1 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.